These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11322491)

  • 1. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy.
    Broglio F; Benso A; Valetto MR; Gottero C; Quaranta L; Podio V; Arvat E; Bobbio M; Bisi G; Ghigo E
    Endocrine; 2001 Feb; 14(1):105-8. PubMed ID: 11322491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy.
    Imazio M; Bobbio M; Broglio F; Benso A; Podio V; Valetto MR; Bisi G; Ghigo E; Trevi GP
    Eur J Heart Fail; 2002 Mar; 4(2):185-91. PubMed ID: 11959048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy.
    Broglio F; Fubini A; Morello M; Arvat E; Aimaretti G; Gianotti L; Boghen MF; Deghenghi R; Mangiardi L; Ghigo E
    Clin Endocrinol (Oxf); 1999 Apr; 50(4):417-30. PubMed ID: 10468900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery.
    Broglio F; Guarracino F; Benso A; Gottero C; Prodam F; Granata R; Avogadri E; Muccioli G; Deghenghi R; Ghigo E
    Eur J Pharmacol; 2002 Jul; 448(2-3):193-200. PubMed ID: 12144941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone-releasing peptides and the cardiovascular system.
    Muccioli G; Broglio F; Valetto MR; Ghè C; Catapano F; Graziani A; Papotti M; Bisi G; Deghenghi R; Ghigo E
    Ann Endocrinol (Paris); 2000 Feb; 61(1):27-31. PubMed ID: 10790589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; Del Rio G; Arvat E; Boghen MF; Deghenghi R; Muccioli G; Ong H; Ghigo E
    J Endocrinol Invest; 1999 Apr; 22(4):266-72. PubMed ID: 10342360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac effects of hexarelin in hypopituitary adults.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; Aimaretti G; Pelosi E; Del Rio G; Muccioli G; Ong H; Boghen MF; Deghenghi R; Ghigo E
    Eur J Pharmacol; 1999 Sep; 381(1):31-8. PubMed ID: 10528131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin.
    De Gennaro Colonna V; Rossoni G; Bernareggi M; Müller EE; Berti F
    Eur J Pharmacol; 1997 Sep; 334(2-3):201-7. PubMed ID: 9369349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone-independent cardioprotective effects of hexarelin in the rat.
    Locatelli V; Rossoni G; Schweiger F; Torsello A; De Gennaro Colonna V; Bernareggi M; Deghenghi R; Müller EE; Berti F
    Endocrinology; 1999 Sep; 140(9):4024-31. PubMed ID: 10465272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.
    Loche S; Cambiaso P; Merola B; Colao A; Faedda A; Imbimbo BP; Deghenghi R; Lombardi G; Cappa M
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2692-6. PubMed ID: 7673411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is cardiac and hepatic iron status assessed by MRI T2* associated with left ventricular function in patients with idiopathic cardiomyopathy?
    Kanzaki Y; Yuki M; Yamamura KI; Narumi Y; Ishizaka N
    Heart Vessels; 2016 Dec; 31(12):1950-1959. PubMed ID: 26897743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexarelin, but not growth hormone, protects heart from damage induced in vitro by calcium deprivation replenishment.
    Torsello A; Rossoni G; Locatelli V; De Gennaro Colonna V; Bernareggi M; Francolini M; Müller EE; Berti F
    Endocrine; 2001 Feb; 14(1):109-12. PubMed ID: 11322492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous growth hormone administration does not inhibit the growth hormone response to hexarelin in normal men.
    Cappa M; Setzu S; Bernardini S; Carta D; Federici G; Grossi A; Loche S
    J Endocrinol Invest; 1995 Nov; 18(10):762-6. PubMed ID: 8787952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GH responsiveness to repeated GHRH or hexarelin administration in normal adults.
    Sartorio A; Conti A; Ferrero S; Spada A; Faglia G
    J Endocrinol Invest; 1995 Oct; 18(9):718-22. PubMed ID: 8719303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency.
    Maheshwari HG; Rahim A; Shalet SM; Baumann G
    J Clin Endocrinol Metab; 1999 Mar; 84(3):956-9. PubMed ID: 10084578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor.
    Gondo RG; Aguiar-Oliveira MH; Hayashida CY; Toledo SP; Abelin N; Levine MA; Bowers CY; Souza AH; Pereira RM; Santos NL; Salvatori R
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3279-83. PubMed ID: 11443201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.
    Loche S; Cambiaso P; Carta D; Setzu S; Imbimbo BP; Borrelli P; Pintor C; Cappa M
    J Clin Endocrinol Metab; 1995 Feb; 80(2):674-8. PubMed ID: 7852535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.